- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Blair William & Co. IL Reduces Bristol Myers Squibb Stake
Institutional investor trims holdings in pharmaceutical company
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
According to a recent 13F filing, Blair William & Co. IL reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 11.7% during the third quarter. The firm now owns 405,640 shares of the biopharmaceutical company's stock, valued at $18.3 million as of the latest SEC filing.
Why it matters
This filing provides insight into the investment decisions of a major institutional investor and could signal a shift in sentiment around Bristol Myers Squibb's stock. As a large pharmaceutical company, changes in ownership by major funds can impact the stock price and trading volume.
The details
Blair William & Co. IL sold 53,545 shares of Bristol Myers Squibb during the third quarter, reducing its total position to 405,640 shares. The firm cited unspecified reasons for the portfolio adjustment, which represented an 11.7% decrease in its Bristol Myers Squibb holdings.
- The 13F filing was submitted in the third quarter of 2026.
The players
Blair William & Co. IL
An institutional investment management firm that reduced its stake in Bristol Myers Squibb.
Bristol Myers Squibb Company
A global biopharmaceutical company focused on discovering, developing and delivering medicines for serious diseases.
The takeaway
This filing highlights the ongoing shifts in institutional ownership of major pharmaceutical stocks like Bristol Myers Squibb. While the reasons for Blair William & Co.'s portfolio adjustment are not specified, it reflects the dynamic nature of the investment landscape and the need for companies to maintain strong relationships with the investment community.
